For non-oncogene addicted NSCLC, PD-1 axis blockade represents the current standard of care in the first-line setting, either as monotherapy or in combination, depending largely on programmed cell death ligand-1 (PD-L1) expression in tumor cells (TPS) [4]. Here, PDCD1 is linked to non-small cell lung carcinoma.